The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Genistein depletes telomerase activity through cross‐talk between genetic and epigenetic mechanisms
Open accessAbstract
Genistein, a natural isoflavone found in soybean products, has been reported to down‐regulate telomerase activity and that this prevents cancer and contributes to the apoptosis of cancer cells. However, the precise molecular mechanism by which genistein represses telomerase is not clear. Here, we show that genistein inhibits the transcription of hTERT (human telomerase reverse transcriptase), the catalytic subunit of the human telomerase enzyme, in breast MCF10AT benign cells and MCF‐7 cancer cells in a time‐ and dose‐dependent manner. Three major DNA methyltransferases (DNMT1, 3a and 3b) were also decreased in genistein‐treated breast cancer cells suggesting that genistein may repress hTERT by impacting epigenetic pathways. Sequential depletion of the hTERT promoter revealed that the hTERT core promoter region is responsible for the genistein‐induced repression of hTERT transcription. Using a newly developed technique of chromatin immunoprecipitation (ChIP)‐related bifulfite sequencing analysis, we found an increased binding of E2F‐1 to the hTERT promoter is due to the site‐specific hypomethylation of the E2F‐1 recognition site. In addition, we found that genistein can remodel chromatin structures of the hTERT promoter by increasing trimethyl‐H3K9 but decreasing dimethyl‐H3K4 in the hTERT promoter. The repression of hTERT was enhanced by combination with genistein and the DNMT inhibitor, 5‐aza‐2′‐deoxycytidine (5‐aza‐dCyd). These findings collectively show that genistein is working, at least in part, through epigenetic mechanisms of telomerase inhibition in breast benign and cancer cells and may facilitate approaches to breast cancer prevention and treatment using an epigenetic modulator combined with genistein. © 2009 UICC
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Guilleret, I., Yan, P., Grange, F., Braunschweig, R., Bosman, F. T., & Benhattar, J. (2002) · International Journal of Cancer · doi:10.1002/ijc.10593 · Cited by 260
Horikawa, I., & Barrett, J. C. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg085 · Cited by 211
Zinn, R. L., Pruitt, K., Eguchi, S., Baylin, S. B., & Herman, J. G. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3396 · Cited by 210
Cited by
Alegría-Torres, J. A., Baccarelli, A., & Bollati, V. (2011) · Epigenomics · doi:10.2217/epi.11.22 · Cited by 587
Overcoming cancer therapeutic bottleneck by drug repurposing
Zhang, Z., Zhou, L., Xie, N., Nice, E. C., Zhang, T., Cui, Y., & Huang, C. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00213-8 · Cited by 516
Cancer chemoprevention by dietary polyphenols: Promising role for epigenetics
Link, A., Balaguer, F., & Goel, A. (2010) · Biochemical Pharmacology · doi:10.1016/j.bcp.2010.06.036 · Cited by 497
Epigenetic diet: impact on the epigenome and cancer
Hardy, T. M., & Tollefsbol, T. O. (2011) · Epigenomics · doi:10.2217/epi.11.71 · Cited by 401
Self-citationSulforaphane Causes Epigenetic Repression of hTERT Expression in Human Breast Cancer Cell Lines
Meeran, S. M., Patel, S. N., & Tollefsbol, T. O. (2010) · PLoS ONE · doi:10.1371/journal.pone.0011457 · Cited by 370
Self-citation
Metadata
- Authors
- Li, Y., Liu, L., Andrews, L. G., & Tollefsbol, T. O.
- Venue
- International Journal of Cancer
- Publisher
- Wiley
- Published
- 2009-04-08
- Volume
- 125
- Issue
- 2
- Pages
- 286-296
- ISSN
- 0020-7136 (ISSN-L)
- 1097-0215
- OpenAlex
- W1998111191
- Cited by
- 194
- References
- 4
- FWCI
- 10.83
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.